Mathematical modelling highlights the crucial role of early childhood immunization in preventing congenital CMV in countries with high CMV seroprevalence
Journal
Vaccine
ISSN
0264-410X
Date Issued
2026-08-21
Author(s)
Sonia Gazeau
Catherine Byrne
Daniel Coombs
Colin Kunzweiler
Renato Calabro Calheiros
John Diaz-Decaro
Soren Gantt
Morgan Craig
Editor(s)
Nakhchivan State University
Nakhchivan State University
DOI
https://doi.org/10.1016/j.vaccine.2026.128788
Abstract
Background: Congenital cytomegalovirus infection (cCMVi) is a major global health problem and a leading cause
of childhood hearing, visual, and intellectual disability. Development of an effective vaccine against CMV is a
high priority, and there is optimism that one will be achieved soon. Previous mathematical modelling to predict
the impact of CMV vaccination in low CMV seroprevalence, high-income populations indicate that vaccinating
infants could be a highly efficient strategy to prevent cCMVi, even with only a modestly effective vaccine (i.e.,
<50% protective against primary infection). However, whether vaccinating infants is optimal in high CMV
seroprevalence settings, where rates of cCMVi are correspondingly higher, is unclear.
Methods: We adjusted our existing agent-based stochastic model to study CMV vaccine efficacy in high seroprevalence
settings (reaching 90%) with Brazil as a test case.
Results: Our results suggest that vaccinating 12-year-old girls and women of childbearing age would have limited
ability to reduce cCMVi rates in Brazil, even with a vaccine conferring complete life-long protection against CMV
infection. In contrast, vaccinating infants was predicted to provide substantial long-term reductions in the
number of cCMVi cases in Brazil, even if it only induced protection equivalent to natural immunity against CMV
reinfection and reactivation. Further, our model predicted that if two-thirds of Brazilian infants were vaccinated,
a modestly effective vaccine would reduce the number of cCMVi cases by up to 76%.
Conclusion: Together with results from other studies, this analysis underscores that infancy is likely the optimal
target age for CMV vaccination to prevent cCMVi in all populations, regardless of the CMV seroprevalence.
Furthermore, our findings predict large reductions in disease due to cCMVi worldwide through attainable
vaccination scenarios.
of childhood hearing, visual, and intellectual disability. Development of an effective vaccine against CMV is a
high priority, and there is optimism that one will be achieved soon. Previous mathematical modelling to predict
the impact of CMV vaccination in low CMV seroprevalence, high-income populations indicate that vaccinating
infants could be a highly efficient strategy to prevent cCMVi, even with only a modestly effective vaccine (i.e.,
<50% protective against primary infection). However, whether vaccinating infants is optimal in high CMV
seroprevalence settings, where rates of cCMVi are correspondingly higher, is unclear.
Methods: We adjusted our existing agent-based stochastic model to study CMV vaccine efficacy in high seroprevalence
settings (reaching 90%) with Brazil as a test case.
Results: Our results suggest that vaccinating 12-year-old girls and women of childbearing age would have limited
ability to reduce cCMVi rates in Brazil, even with a vaccine conferring complete life-long protection against CMV
infection. In contrast, vaccinating infants was predicted to provide substantial long-term reductions in the
number of cCMVi cases in Brazil, even if it only induced protection equivalent to natural immunity against CMV
reinfection and reactivation. Further, our model predicted that if two-thirds of Brazilian infants were vaccinated,
a modestly effective vaccine would reduce the number of cCMVi cases by up to 76%.
Conclusion: Together with results from other studies, this analysis underscores that infancy is likely the optimal
target age for CMV vaccination to prevent cCMVi in all populations, regardless of the CMV seroprevalence.
Furthermore, our findings predict large reductions in disease due to cCMVi worldwide through attainable
vaccination scenarios.
Subjects
File(s)![Thumbnail Image]()
Loading...
Name
1-s2.0-S0264410X26005979-main.pdf
Size
4.91 MB
Format
Adobe PDF
Checksum
(MD5):f95f9b8610e1889791535dbfce0e610c
